Predictors of ACEI/ARB therapy in patients with hypertrophic cardiomyopathy : results of a national registry

Martins, E.; Lebreiro, A.; Sousa, C.; Leite, S.; Sousa, A.; Belo, A.; Brito, Dulce; Cardim, N.

http://hdl.handle.net/10451/40136

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
P3544.pdf		362.22 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Introduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are not considered disease-modifying drugs in hypertrophic cardiomyopathy (HCM) and their use is usually dependent on other clinical indications. Few data exist about the use of ACEI/ARB in HC in the real world, particularly in patients with intraventricular obstruction. Objective: In this study, we sought to determine the frequency of ACEI / ARB therapy in patients with HCM and the predictors for their use.